Evidence map›Paper›PMID 40923683›Full record

ArticlePediatric pulmonology2025

Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis.

Susanne Ursula Trost, Tasma Harindhanavudhi, Qi Wang, Anvitha Ankireddypalli, Azmi Simrah, Sreekant Avula, Amir Moheet

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Impact of Genetics on Endocrine Manifestations of Cystic Fibrosis.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
    Review
  2. Updates in Cystic Fibrosis Bone Disease in Adults.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
    Review
  3. The impact of elexacaftor-tezacaftor-ivacaftor on cardiometabolic risk factors: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Susanne Ursula TrostDepartment of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-8000-1323
Tasma HarindhanavudhiDepartment of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.
Qi WangClinical and Transitional Science Institute, University of Minnesota, Minneapolis, Minnesota, USA.
Anvitha AnkireddypalliDepartment of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.
Azmi SimrahDepartment of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.
Sreekant AvulaDepartment of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.
Amir MoheetDepartment of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.

Funding

The authors received no specific funding for this work.
6 · The paper itself

Abstract

backgroundThe approval of cystic fibrosis transmembrane conductance regulator modulators elexacaftor/tezacaftor/ivacaftor (ETI), has significantly improved pulmonary function for people with cystic fibrosis (pwCF). However, the effects on CF-related bone disease and body composition remain unclear.

methodsThis retrospective real-world study examined adults with CF who received ETI treatment. Bone density and body composition were measured via dual-energy X-ray absorptiometry (DXA) 1.8 (SD 0.7) years before (preDXA) and 1.5 (SD 0.4) years after ETI initiation (postDXA1). In a subgroup, measurements were also available 4 (SD 0.6) years after initiation (postDXA2).

resultsThe study included 74 pwCF, of whom 42% were female, with an average age of 38.9 (SD 9.3) years at ETI initiation. Bone density decreased significantly at the spine (p = 0.02), left hip (p < 0.01), and right hip (p < 0.01) from pre- to postDXA1. No significant change in bone density was observed when comparing postDXA1 to postDXA2. Body composition analysis revealed significant increases in weight in both females (p < 0.01) and males (p < 0.01), as well as increases in fat mass in females (p < 0.01) and males (p < 0.01), without significant changes in lean mass (p = 0.4).

conclusionsBone density declined significantly during the study period, with the most pronounced decline occurring in the first 1.5 years after ETI initiation. However, this decline appeared to stabilize in participants with longer follow-up at 4 years post-ETI treatment, suggesting potential bone-protective effects with prolonged therapy. Body weight and fat mass increased early after ETI initiation, suggesting metabolic changes accompanying CFTR modulation.

Indexed as

AminophenolsBenzodioxolesBody CompositionBone DensityCystic FibrosisIndolesPyrazolesPyridinesPyrrolidinesQuinolonesAbsorptiometry, PhotonAdultCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsFemaleHumansAminophenolsBenzodioxolesCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationselexacaftorIndolesivacaftorPyrazolesPyridinesPyrrolidinesQuinolonestezacaftorbody compositionbone densitybone healthcystic fibrosiselexacaftor/tezacaftor/ivacaftorfat mass

Identifiers

PMID40923683
PMCPMC12418912

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.